Anest. intenziv. Med. 2008;19(1):12-15

Is haemocoagulation inhibitor therapy in sepsis appropriate?Intensive Care Medicine

J. Blatný*, O. Zapletal
Oddělení klinické hematologie, Fakultní nemocnice Brno

This review focuses on the problems and questions regarding the treatment of septic patients using coagulation inhibitor concentrates from the haematologist's point of view. Currently available published data are reviewed and summarised and on its basis recommendations for the administration of commercially available coagulation inhibitor concentrates (mainly AT, PC, aPC and heparins) are formulated.

Keywords: sepsis coagulation; antithrombin; heparin; protein C; bleeding; thrombosis

Published: February 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Blatný J, Zapletal O. Is haemocoagulation inhibitor therapy in sepsis appropriate? Anest. intenziv. Med. 2008;19(1):12-15.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. van der Poll, T. Coagulation and inflammation. J. Endotoxin. Res., 2001, 7, 4, p. 301-304. Go to original source... Go to PubMed...
    2. Kolde, H. J. Haemostasis. 2nd edition, 2004.
    3. Nathan and Oski's hematology of infanty and childhood. 6th edition.
    4. Hoffmann, J. N., Wiedermann, C. J., Juers, M., Ostermann, H., Kienast, J., Briegel, J., Strauss, R., Warren, B. L., Opal, S. M. KyberSept investigators, Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb. Haemost., 2006, 95, p. 850-856. Go to original source... Go to PubMed...
    5. Bucur, S. Z., Levy, J. H., Despotis, G. J., Spiess, B. D., Hillyer, C. D. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion, 1998, 38, p. 481-498. Go to original source... Go to PubMed...
    6. Sorg, H., Hoffmann, J. N., Menger, M. D., Lindenblatt, N., Goehring, P., Vollmar, B. Antithrombin is as effective as heparin and hirudin to prevent formation of microvascular thrombosis in a murine model. Thromb. Haemost., 2006, 96, p. 371-377. Go to original source... Go to PubMed...
    7. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results. Prescrire Int., 2007, 16, 87, p. 7-9. Go to PubMed...
    8. McCoy, C. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis. Expert Opin. Drug Saf., 2004, 3, 6, p. 625-637. Go to original source... Go to PubMed...
    9. Haley, M., Cui, X., Minneci, P. C., Deans, K. J., Natanson, C., Eichacker, P. Q. Recombinant human activated protein C in sepsis: assessing its clinical use. Am. J. Med. Sci., 2004, 328, p. 215-219. Go to original source... Go to PubMed...
    10. Nadel, S., Goldstein, B., Williams, M. D., Dalton, H., Peters, M., Macias, W. L., Abd-Allah, S. A., Levy, H., Angle, R., Wang, D., Sundin, D. P., Giroir, B. REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspectiVE (RESOLVE) study group., Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet, 2007, 10, 369, 9564, p. 836-843. Go to original source... Go to PubMed...
    11. Levi, M., Levy, M., Williams, M. D., Douglas, I., Artigas, A., Antonelli, M., Wyncoll, D., Janes, J., Booth, F. V., Wang, D., Sundin, D. P., Macias, W. L., for the Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am. J. Respir. Crit. Care Med., 2007, 176, p. 483-490. (Epub 2007 Jun 7) Go to original source... Go to PubMed...
    12. Ettingshausen, C. E., Veldmann, A., Beeg, T., Schneider, W., Jager, G., Kreuz, W. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin. Thromb. Hemost., 1999, 25, p. 537-541. Go to original source... Go to PubMed...
    13. Kreuz, W., Veldmann, A., Fischer, D., Schlosser, R., Volk, W. R., Ettingshausen, C. E. Neonatal sepsis: a challenge in hemostaseology. Semin. Thromb. Hemost., 1999, 25, p. 531-535. Go to original source... Go to PubMed...
    14. Smith, O. P., White, B., Vaughan, D., Rafferty, M., Claffey, L., Lyons, B., Casey, W. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet, 1997, 29, 350, 9091, p. 1590-1593. Go to original source... Go to PubMed...
    15. de Kleijn, E. D., de Groot, R., Hack, C. E., Mulder, P. G., Engl, W., Moritz, B., Joosten, K. F., Hazelzet, J. A. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit. Care Med., 2003, 31, p. 1839-1847. Go to original source... Go to PubMed...
    16. Robertson, M. S. Heparin: the cheap alternative for immunomodulation in sepsis? Crit. Care Resusc., 2006, 8, 3, p. 235-238. Go to original source... Go to PubMed...
    17. Warren, B. L., Eid, A., Singer, P., Pillay, S. S., Carl, P., Novak, I., Chalupa, P., Atherstone, A., Penzes, I., Kubler, A., Knaub, S., Keinecke, H. O., Heinrichs, H., Schindel, F., Juers, M., Bone, R. C., Opal, S. M., KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA, 2001, 286, p. 1869-1878. (Erratum in: JAMA 2002, 287, p. 192) Go to original source... Go to PubMed...

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.